Expert Panel Review and Practical Guidance on Biomarker Testing With Engineered Immune Effector Cells.
Cancer specialists agreed on which blood tests best predict who will struggle with CAR-T side effects, helping doctors prepare for and manage complications.
An ASTCT multidisciplinary expert panel developed consensus recommendations for standardized biomarker testing in CAR-T cell therapy, stratifying laboratory assays, cytokine profiles, and CAR-T expansion/persistence monitoring by clinical utility tiers. Harmonized cytokine and CAR-T kinetic biomarkers were endorsed as promising dynamic predictors of CRS, ICANS, and treatment failure to enable cross-study comparability.
What the study was
- Study design
- Expert consensus panel / evidence review
- Population
- CAR-T cell therapy recipients across hematologic malignancies
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Transplantation and Cellular Therapy
Why it surfaced
ASTCT consensus from major US/EU CAR-T centers; directly actionable for clinical labs managing CAR-T patients; highest relevance score given broad CAR-T application across hematologic malignancies.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.